

        An individual who meets any of the following criteria will be excluded from participation
        in this study:

          1. Meeting alternative indication for higher-dose anticoagulation

               1. Prevalent blood clot at the time of enrollment

               2. On renal replacement therapies (CRRT, CVVH)

               3. D-dimer >10,000 ng/ml

               4. Change in D-dimer >6X over the admission lab value

               5. Renal failure requiring renal replacement therapy

               6. Prior VTE

               7. Atrial fibrillation (with a CHADS2 Score >1) on oral anticoagulant therapy
                  already

          2. Prior Heparin induced thrombocytopenia within 100 days

          3. Stroke within 30 days

          4. Prior hemorrhagic stroke (ever)

          5. GI bleed within the past 6 months

          6. Platelet count <100,000

          7. Pregnancy

          8. Anemia with a hemoglobin <9mg/dl

          9. Signs of active bleeding (e.g. requirement of a blood transfusion in the past 30 days)

         10. Other high bleeding risk (I.e. trauma, use of dual antiplatelet therapy)

         11. Renal failure on admission (by RIFLE criteria 3X change in serum creatinine from
             baseline or >75% reduction in GFR or urine output <0.3ml/kg over 24 hours or anuria
             for 12 hours)

         12. Subjects who have no capacity to consent for themselves.
      